IL309160A - Subcutaneous formulation and methods for the treatment of edema resistant to oral diuretics - Google Patents

Subcutaneous formulation and methods for the treatment of edema resistant to oral diuretics

Info

Publication number
IL309160A
IL309160A IL309160A IL30916023A IL309160A IL 309160 A IL309160 A IL 309160A IL 309160 A IL309160 A IL 309160A IL 30916023 A IL30916023 A IL 30916023A IL 309160 A IL309160 A IL 309160A
Authority
IL
Israel
Prior art keywords
methods
treating edema
subcutaneous formulation
oral diuretics
refractory
Prior art date
Application number
IL309160A
Other languages
English (en)
Hebrew (he)
Original Assignee
RESQ Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RESQ Pharmaceuticals LLC filed Critical RESQ Pharmaceuticals LLC
Publication of IL309160A publication Critical patent/IL309160A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL309160A 2021-06-09 2022-06-09 Subcutaneous formulation and methods for the treatment of edema resistant to oral diuretics IL309160A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163208863P 2021-06-09 2021-06-09
PCT/US2022/032862 WO2022261344A1 (en) 2021-06-09 2022-06-09 Subcutaneous formulation and methods for treating edema refractory to oral diuretics

Publications (1)

Publication Number Publication Date
IL309160A true IL309160A (en) 2024-02-01

Family

ID=84425561

Family Applications (1)

Application Number Title Priority Date Filing Date
IL309160A IL309160A (en) 2021-06-09 2022-06-09 Subcutaneous formulation and methods for the treatment of edema resistant to oral diuretics

Country Status (10)

Country Link
US (1) US20240285566A1 (https=)
EP (1) EP4351554A4 (https=)
JP (1) JP2024520788A (https=)
KR (1) KR20240042402A (https=)
CN (1) CN117915905A (https=)
AU (1) AU2022289724A1 (https=)
BR (1) BR112023025880A2 (https=)
CA (1) CA3221710A1 (https=)
IL (1) IL309160A (https=)
WO (1) WO2022261344A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293429A (en) 2019-12-04 2022-07-01 RESQ Pharmaceuticals LLC Methods and preparations for the treatment of edema resistant to oral diuretics

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040105818A1 (en) * 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7906555B2 (en) * 2006-10-26 2011-03-15 Arizona Board Of Regents On Behalf Of The University Of Arizona Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
US20140128469A1 (en) * 2011-05-10 2014-05-08 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
US20210163406A1 (en) * 2018-04-06 2021-06-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Bumetanide Derivatives for the Therapy of Stroke and Other Neurological Diseases/Disorders Involving NKCCs
IL293429A (en) * 2019-12-04 2022-07-01 RESQ Pharmaceuticals LLC Methods and preparations for the treatment of edema resistant to oral diuretics

Also Published As

Publication number Publication date
BR112023025880A2 (pt) 2024-02-27
KR20240042402A (ko) 2024-04-02
CA3221710A1 (en) 2022-12-15
WO2022261344A1 (en) 2022-12-15
EP4351554A4 (en) 2025-05-07
AU2022289724A1 (en) 2024-01-18
JP2024520788A (ja) 2024-05-24
US20240285566A1 (en) 2024-08-29
EP4351554A1 (en) 2024-04-17
CN117915905A (zh) 2024-04-19
WO2022261344A8 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
AU2018243463A8 (en) 11,13-modified saxitoxins for the treatment of pain
EP4069222A4 (en) METHODS AND COMPOSITIONS FOR TREATING EDEMA NOT RESPONSIVE TO ORAL DIURETICS
MX2020011653A (es) Métodos de tratamiento para el abuso de sustancias.
MX2015012866A (es) Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
NZ720813A (en) Composition and method for aiding sleep
PH12017500933A1 (en) Sublingual administration of riluzole
SG10201810401RA (en) Pharmaceutical combinations for treating cancer
PH12017500934B1 (en) Sublingual formulation of riluzole
GB201206486D0 (en) Vesicular formulations and uses thereof
MX2017015012A (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
ZA202211665B (en) Ammonia oxidizing bacteria for treatment of acne
IL267958A (en) An injectable preparation that can be used to treat heart diseases and contains fibroblasts, and a method for producing fibroblasts for medical use
MX2021010286A (es) Formas de dosificacion de la hormona del crecimiento de accion prolongada con eficacia superior a la somatropina diaria.
IL309160A (en) Subcutaneous formulation and methods for the treatment of edema resistant to oral diuretics
MX2019013864A (es) Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo.
SG10201811203TA (en) Protocols for treatment of major depressive disorder (mdd)
MX2024009649A (es) Tratamiento de la tos cronica, la dificultad respiratoria y la disnea.
MX2019004804A (es) Tratamiento para el prurigo nodula.
HK40110450A (en) Subcutaneous formulation and methods for treating edema refractory to oral diuretics
WO2019179823A8 (en) Lactobacillus fermentum for treating fructose-related diseases
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
GEP20196947B (en) Bremelanotide therapy for female sexual dysfunction
SG10201809280PA (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
GB202116267D0 (en) Improvements relating to ore treatment
PH22019000676U3 (en) Organic mulberry leaf water extract having anticlastogenic activity and method of production thereof